XEL-002BI

N/A

Report date: 2025/01/26 17:14:33

NME

Base Information

Drug NameXEL-002BI

Drug Alias NameBulleyaconitine A drug implant(Xel Pharmaceuticals)voltage gated sodium channel inhibitor (Xel Pharmaceuticals)Voltage Gated Sodium Channel Inhibitor (Xel Pharmaceuticals)XEL-002BI

ClassificationSmall moleculesNatural product/Extract

Mechanisms of ActionVoltage-gated sodium channels blockers

TargetsVoltage-gated sodium channels

Therapy Area/IndicationsPainInflammation

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesXel Pharmaceuticals Inc

China Registration ClassN/A

Develop Information

Active CompaniesXel Pharmaceuticals Inc

Inactive CompaniesN/A

Active IndicationsPainInflammation

Inactive IndicationsN/A

Other Information

ATC CodeN/A